Intensification of antiretroviral therapy through addition of enfuvirtide in naive hiv-1-infected patients with severe immunosuppression does not improve immunological response: Results of a randomized multicenter trial (ANRS 130 Apollo)

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 758-765

  Joly, Véronique ^a   Fagard, Catherine ^b   Grondin, Carine ^a   Descamps, Diane ^a   Yazdanpanah, Yazdan ^a,c   Charpentier, Charlotte ^a   De Verdiere, Nathalie Colin ^d   Tabuteau, Sophie ^e   Raffi, Francois ^f   Cabie, André ^g   Chene, Geneviève ^h   Yeni, Patrick ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE LILLE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g Hopital Pierre Zodba Quitman   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLICULITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KAPOSI SARCOMA; LABORATORY TEST; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SIDE EFFECT; THROMBOCYTE; TOXOPLASMOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; LOPINAVIR; MALE; ORGANOPHOSPHONATES; PEPTIDE FRAGMENTS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872842934     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01662-12     Document Type: Article

References (32)

1. Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, HIV Outpatient Study Investigators. 2006. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43:27-34.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M. 1997. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study. BMJ 315: 1194-1199.
3. Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, Dinubile NJ, Harvey CM, Chen J, Leavitt RY, Protocol 039 Study Team. 2003. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clin. Infect. Dis. 37:1119-1124.
4. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J. 1998. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 35:543-549.
5. Egger M, May T, Chêne G, Phillips AN, Lederberger B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, Cohort Collaboration ART. 2002. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 360:119-129.
6. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D, ANRS C004 French Hospital Database on HIV Clinical Epidemiological Group. 2007. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir. Ther. 12:89-96.
7. Girardi E, Sabin CA, Monforte AA. 2007. Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. J. Acquir. Immune Defic. Syndr. 46(Suppl 1):S3-S8.
8. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, Prinz B, Youle M, Johnson MA. 2004. Late presenters in era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS 18:2145-2151.
9. Dheda K, Lampe FC, Johnson MA, Lipman FC. 2004. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J. Infect. Dis. 190:1670-1676.
10. Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, Antiretroviral Therapy (ART) Cohort Collaboration. 2003. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 362:679-686.
11. Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D. 2000. Clinical outcomes of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133: 401-410.
12. Zolopa AR, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L. 2009. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One 4:e5575. doi:10.1371 /journal.pone.0005575.
13. Koethe JR, Limbada MI, Giganti MJ, Nyirenda CK, Mulenga L, Wester CW, Chi BH, Stringer JS. 2010. Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in urban Zambia. AIDS 24:2117-2121.
14. Kaplan JE, Masur H, Holmes KK, USPHS, Infectious Disease Society of America. 2002. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recommend. Rep. 51(RR8):1-52.
15. French MA, Price P, Stone SF. 2004. Immune restoration disease after antiretroviral therapy. AIDS 18:1615-1627.
16. Sobrino Vegas P, Garcia San Miguel L, Caro Murillo AM, Miró JM, Viciana P, Tural C, Saumoy M, Santos I, Sola J, del Amo J, Moreno S, CoRIS. 2009. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact on mortality. Curr. HIV Res. 7:224-230.
17. Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, Balzano R, Vigevani G, Alberici F, Ursitti M, D'Alessandro M, D'Arminio Monforte A, Ippolito G, for the ICoNA Behavioural Epidemiology Study Group. 2004. Delayed presentation and late testing for HIV: Demographic and behavioral risk factors in a multicenter study in Italy. J. Acquir. Immune Defic. Syndr. 36:951-959.
18. Dennis AM, Napravnik S, Sena AC, Eron JJ. 2011. Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin. Infect. Dis. 53:480-487.
19. Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. 2007. Delayed presentation for human immunodeficiency virus (HIV) care among veterans. Med. Care 45:1105-1109.
20. Delpierre C, Dray-Spira R, Cuzin L, Marchou B, Massip P, Lang T, Lert F, Study Group VESPA. 2007. Correlates of late HIV diagnosis: Implications for testing policy. Int. J. STD AIDS 18:312-317.
21. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D, Clinical Epidemiology Group of French Hospital Database on HIV Infection. 2006. Predictors identified for losses to follow-up among HIV-seropositive patients. J. Clin. Epidemiol. 59:829-835.
22. Shafer RW, Smeaton LM, Robbins De Gruttola GK V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team. 2003. Comparison of four-drugs regimen and pairs of sequential three-drugs regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349:2304-2315.
23. Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B, for the INITIO Trial International Co-ordinating Com-mittee. 2006. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITO: Open-label randomized trial. Lancet 368:287-298.
24. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH, Adult AIDS Clinical Trials Group 388 Study Team. 2003. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen in advanced human immunodeficiency virus disease. J. Infect. Dis. 188:625-634.
25. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, III, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team. 2006. Three-versus four-drugs antiretroviral regimens for the initial treatment of HIV-1 infection. A randomized controlled trial. JAMA 296:769-781.
26. Bonora S, Calcagno C, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A, Di Perri G. 2012. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: A controlled pilot study. Infection 40:69-75.
27. Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, Colin de Verdière N, Raffi F, Yeni P, Descamps D on behalf the ANRS 130 APOLLO Trial Study Group. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. J. Antimicrob. Chemother., in press.
28. Miro JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, LoncÁ M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM, Advanz Study Group. 2010. Immune reconstitution in severely immunosuppressed antiretroviral-naïve HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: Three-year results (The Advanz Trial): A randomized, controlled trial. AIDS Res. Hum. Retroviruses 26:747-757.
29. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML. 2000. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 1:107-115.
30. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zeriav S, Djurkovic-Djakovic O. 2005. The prevalence and risk of immune restoration disease in HIVinfected patients treated with highly active antiretroviral therapy. HIV Med. 6:140-143.
31. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. 2006. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis. 42:418-427.
32. Manzardo C, Zacarelli M, Aguero F, Antinori A, Miro JM. 2007. Optimal timing and best antiretroviral regimen in treatment-naïve HIVinfected individuals with advanced disease. J. Acquir. Immune Defic. Syndr. 46(Suppl 1):S9-S18.